< Back to Current Version

Hemp Restrictions in FY2026 Agriculture Appropriations

Changes from June 13, 2025 to July 17, 2025

This page shows textual changes in the document between the two versions indicated in the dates above. Textual matter removed in the later version is indicated with red strikethrough and textual matter added in the later version is indicated with blue.


Hemp Restrictions in the House FY2026 Agriculture Appropriations Draft Bill
June 13 Updated July 17, 2025 (IN12565)

On June 5, 2025, the House Agriculture Appropriations Subcommittee voted to send a markup for an FY2026 appropriations bill to the full committee. The full House Appropriations Committee began consideration of the draft bill on June 11 but postponed a final vote. Among its many provisions, the draft bill includes a provision that effectively would prohibit the commercial production, sale, and distribution of hemp-derived cannabinoid products. Similar action was debated but not enacted in the 118th Congress.

The House Agriculture appropriations markup would amend the statutory definition of hemp to clarify the types of hemp The House and Senate Committees on Appropriations have approved FY2026 Agriculture appropriations bills (H.R. 4121 and S. 2256) that would similarly redefine the statutory definition of hemp to restrict the commercial production, sale, and distribution of certain hemp-derived cannabinoid products. House appropriators have expressed that the provision would close "the hemp loophole that has resulted in the proliferation of unregulated intoxicating hemp products." During Senate committee markup, Senator Mitch McConnell expressed that the existing hemp definition has resulted in "an unintended consequence that has allowed for intoxicating hemp-derived synthetic products to be made and sold," calling for changes to reflect "the original intent of the 2018 farm bill" by closing the loophole. The Senate provision would delay implementation for one year; the House provision does not include this delay. Similar action was debated but not enacted in the 118th Congress. The House and Senate provisions would amend the hemp definition to clarify the types of products considered lawful under the Domestic Hemp Production Program (7 U.S.C. §§1639o-s) administered by the U.S. Department of Agriculture (USDA). The current statutory definition of hemp was established in the Agriculture Improvement Act of 2018 (P.L. 115-334), which legalized hemp cultivation by excluding it from the definition of marijuana (21 U.S.C. §802(16)) and removed, thus removing federal regulation of hemp from the Controlled Substances Act (CSA; 21 U.S.C. §§801 et seq.) and oversight by thefrom U.S. Drug Enforcement Administration (DEA) oversight. . Both hemp and marijuana are from the Cannabis sativa plant. Congress also preserved the laws and regulations of the Food and Drug Administration (FDA) and the Federal Food, Drug, and Cosmetic Act (FFDCA; 21 U.S.C. §§301 et seq.) regarding hemp-derived products (7 U.S.C. §1639r(c)), leading FDA to assert that consumer products containing cannabis and cannabis-derived cannabinoids under its jurisdiction are "unlawful."

Hemp Both hemp and marijuana are from the Cannabis sativa plant. In statute, hemp is currently defined to mean "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol [THC] concentration of not more than 0.3 percent on a dry weight basis" (7 U.S.C. §1639o). There are hundreds of chemical compounds and cannabinoids in the cannabis plant.

The draft appropriations bill would expand on H.R. 4121 (§759) and S. 2256 (§781, as amended) would expand the existing statutory definition of hemphemp to include industrial hemp products and exclude certain hemp-derived cannabinoid products (§759). The provision would define these two terms. These terms would be defined as follows:

  • Industrial hemp would be defined to meanas hemp grown for "non-cannabinoid" uses, including for fiber or for grain/seed (e.g., use as a whole grain, oil, cake, nut, or hull) or for immature plants (e.g., "microgreens or other edible hemp leaf products"), as well as hemp grown for research purposes or as a viable seed to produce industrial hemp.
  • Hemp-derived cannabinoid product would be defined to meanas "any intermediate or final product derived from hemp (other than industrial hemp), that ... contains cannabinoids in any form; and ... is intended for human or animal use through any means of application or administration, such as inhalation, ingestion, or topical application."

Excluding hemp-derived cannabinoid products from the federal definition of hemp effectively would prohibit production and sale of hemp-derived cannabinoids, derivatives, and extracts thereof, including cannabidiol (CBD). Excluded cannabinoids would cover also non-naturally occurring and synthesized or manufactured compounds. The proposed provision would make other broader changes to the hemp definition by changingThe provisions would exclude from the hemp definition any cannabinoids that are non-naturally occurring and synthesized or manufactured compounds. The provisions also would exclude from the definition "any viable seeds from a Cannabis sativa L. plant" that exceed a total THC (including tetrahydrocannabinolic acid [THCA]) of 0.3% in the plant on a dry weight basis. Other changes would provide that the allowable limits of THC—the leading psychoactive cannabinoid in the cannabis plant—to be determined on the basis of its total THC, including tetrahydrocannabinolic acid (THCA)THCA, instead of delta-9 THC. This would codify the regulatory practice established in USDA's 2021 final hemp regulations. The provision would exclude from hemp "any viable seeds from a Cannabis sativa L. plant" that exceed a total THC (including THCA) of 0.3% in the plant on a dry weight basis.

The draft appropriations measure also would exclude from the statutory definition of hempOther existing statutory language regarding hemp "derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not" would remain unchanged. The provisions would exclude "any hemp-derived cannabinoid products containing ... quantifiable amounts based on substance, form, manufacture, or article" of THC as determined by the Secretary of Health and Human Services (HHS) in consultation with the Secretary of Agriculture. A draft of the committee report to accompany the draft bill would furtherUSDA Secretary. The House committee report would require that FDA establish a task force to "provide input on determining the level of quantifiable amounts of [THC] or other cannabinoids in hemp-derived cannabinoid products" and recommend "clear, science-based guidance to ensure product safety, consumer confidence, and regulatory clarity" for hemp-derived products. The manager's amendment to the report states, " (H.Rept. 119-172). In determining the quantifiable amounts, the Committee House committee states it "does not intend for industrial or non-intoxicating hemp-derived cannabinoid products with trace or insignificant amounts of THC to be affected."

The House Agriculture Appropriations Committee's press release says the hemp provision "supports the Trump Administration and mandate of the American people by ... closing the hemp loophole that has resulted in the proliferation of unregulated intoxicating hemp products, including [d]elta-8 and hemp flower, being sold online and in gas stations across the country." This proposed policy change broadly reflects the efforts of the Cannabis Regulators Association (CANNRA) and the attorneys general across several states. In general, the "loophole" refers to the marketing While neither the House nor Senate describes what constitutes an intoxicating hemp-derived cannabinoid product, these proposed changes would effectively redefine hemp to include any industrial hemp product but include only hemp cannabinoid products that are naturally occurring, non-synthetic, and nonintoxicating. The Senate committee report would require FDA to report on projected market impacts and stakeholder engagement, including information on uniform packaging, labeling, testing, and adverse event reporting requirements (S.Rept. 119-37). Efforts to close the hemp loophole reflect recommendations of the Cannabis Regulators Association (CANNRA) and attorneys general in several states. CANNRA has identified three loopholes—0.3% loophole, THCA loophole, and derivatives loophole—that it asserts are being used to justify the sale of unregulated hemp-derived cannabinoid products despite some products being widely considered to be intoxicating and to pose public safety and health risks. CANNRA has identified three loopholes—0.3% loophole, THCA loophole, and derivatives loophole—which they assert are being used to justify the sale of intoxicating hemp-derived products. The draft provision largely addressesThe House and Senate provisions would address the first two loopholes by codifying USDA requirements that hemp be tested on the basis of total THC (including THCA); the third is. The third would be addressed by the exclusion of certain hemp-derived cannabinoid products in the definition of hemp. Industry groups contend that the proposed policy change—intoxicating hemp-derived cannabinoid products would be considered controlled substances, subject to DEA enforcement. Industry groups contend such policy changes would "dismantle" the U.S. hemp industry.

The 118th Congress considered but did not enact similar provisionssimilar changes to the hemp definition. The House Agriculture Committee includedadded a nearly identical provision to its farm bill proposal nearly identical changes to the hemp definition in the Farm, Food, and National Security Act of 2024 (H.R. 8467, §10006, as amended and ordered to be reported). The House Agriculture Appropriations Committee's FY2025 appropriations bill; House appropriators added a related provision to FY2025 Agriculture appropriations (H.R. 9027, §760)) included a similar provision. While appropriations acts usually do not amendamend the U.S. Code, it is possiblethey may do so depending on the use of House rules.